Jim Cramer answers viewers’ stock questions from the floor of the New York Stock Exchange. He says although typically one is supposed to sell biotech stocks here, he believes the group has gotten under-owned. He likes two speculative biotech names, Receptos (RCPT) and Radius Health (RDUS), as well as the four horsemen, which are Biogen (BIIB), Gilead (GILD), Celgene (CELG) and Regeneron (REGN). In terms of the IT industry, Cramer says he believes Cognizant’s (CTSH) multiple is too low and it’s going higher. He also stresses that Facebook (FB) continues to deliver on every metric and the stock has gotten too cheap. He recommends owning it instead of trading it. Send in your questions for Jim on Twitter (TWTR) using #CramerQ.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
